The Significance of Continuous Dopaminergic Stimulation in the Treatment of Parkinson’s Disease Thomas N. Chase OriginalPaper 15 November 2012 Pages: 1 - 9
Pharmacodynamic and Pharmacokinetic Features of Cabergoline R. G. Fariello OriginalPaper 15 November 2012 Pages: 10 - 16
Clinical Experience with Cabergoline in Patients with Advanced Parkinson’s Disease Treated with Levodopa C. David Marsden OriginalPaper 15 November 2012 Pages: 17 - 22
Early Treatment of Parkinson’s Disease with Cabergoline Delays the Onset of Motor Complications U. K. RinneF. BraccoC. D. Marsden OriginalPaper 15 November 2012 Pages: 23 - 30
